Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
In multivariable analyses conducted by several groups, a post-therapy decline in prostate specific antigen was the most significant factor associated with survival of patients with relapsed prostate cancer. Contemporary combination regimens result in consistent declines in prostate-specific antigen in up to 40% of cases, along with objective tumour regression, and the improvement in cancer-related symptoms. It is, therefore, apparent that prostate cancers are not as resistant to treatment as previously believed.
Scher
H I
HI
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003599:Cytoskeleton / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen